Evidence map›Paper›PMID 38601145›Full record

ArticleFrontiers in immunology2024

A generalizable and easy-to-use COVID-19 stratification model for the next pandemic via immune-phenotyping and machine learning.

Xinlei He, Xiao Cui, Zhiling Zhao, Rui Wu, Qiang Zhang, Lei Xue, Hua Zhang, Qinggang Ge, Yuxin Leng

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xinlei He *Department of Intensive Care Unit, Peking University Third Hospital, Beijing, China.
Xiao Cui *Department of Intensive Care Unit, Peking University Third Hospital, Beijing, China.
Zhiling Zhao *Department of Intensive Care Unit, Peking University Third Hospital, Beijing, China.
Rui WuDepartment of Pulmonary and Critical Care Medicine, Peking University Third Hospital, Beijing, China.
Qiang ZhangDepartment of Intensive Care Unit, Peking University Third Hospital, Beijing, China.
Lei XueDepartment of Intensive Care Unit, Peking University Third Hospital, Beijing, China.
Hua ZhangDepartment of Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
Qinggang GeDepartment of Intensive Care Unit, Peking University Third Hospital, Beijing, China.
Yuxin LengDepartment of Intensive Care Unit, Peking University Third Hospital, Beijing, China.
Peking University Third Hospital · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The coronavirus disease 2019 (COVID-19) pandemic has affected billions of people worldwide, and the lessons learned need to be concluded to get better prepared for the next pandemic. Early identification of high-risk patients is important for appropriate treatment and distribution of medical resources. A generalizable and easy-to-use COVID-19 severity stratification model is vital and may provide references for clinicians. Methods: Three COVID-19 cohorts (one discovery cohort and two validation cohorts) were included. Longitudinal peripheral blood mononuclear cells were collected from the discovery cohort (n = 39, mild = 15, critical = 24). The immune characteristics of COVID-19 and critical COVID-19 were analyzed by comparison with those of healthy volunteers (n = 16) and patients with mild COVID-19 using mass cytometry by time of flight (CyTOF). Subsequently, machine learning models were developed based on immune signatures and the most valuable laboratory parameters that performed well in distinguishing mild from critical cases. Finally, single-cell RNA sequencing data from a published study (n = 43) and electronic health records from a prospective cohort study (n = 840) were used to verify the role of crucial clinical laboratory and immune signature parameters in the stratification of COVID-19 severity. Results: Patients with COVID-19 were determined with disturbed glucose and tryptophan metabolism in two major innate immune clusters. Critical patients were further characterized by significant depletion of classical dendritic cells (cDCs), regulatory T cells (Tregs), and CD4 Conclusion: Overall, we developed and validated a generalizable and easy-to-use COVID-19 severity stratification model using machine learning algorithms. The level of cDCs and LDH will assist clinicians in making quick decisions during future pandemics.

Indexed as

COVID-19HumansLeukocytes, MononuclearL-Lactate DehydrogenaseMachine LearningPandemicsProspective StudiesSARS-CoV-2L-Lactate Dehydrogenaseclassical dendritic cellsCOVID-19decision-makinglactate dehydrogenasemachine learningmass cytometry by time of flight (CyTOF)severity stratification

Identifiers

PMID38601145
PMCPMC11004273
OpenAlexW4393229329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.